Trevi Therapeutics Stock Price, News & Analysis

Trevi Therapeutics (TRVI) announced significant upcoming updates regarding its clinical trials. An interim statistical update for the Phase 2 CANAL trial, evaluating Haduvio for chronic cough in idiopathic pulmonary fibrosis (IPF) patients, is expected in Q1 2022. Additionally, enrollment in the Phase 2b/3 PRISM trial for pruritus related to prurigo nodularis will conclude by January 31, 2022. These trials are pivotal, as there are currently no approved treatments for these conditions, underscoring the urgent need for effective therapies.

Trevi Therapeutics, a clinical-stage biopharmaceutical company, will participate in several virtual conferences in January 2022. These include the 11th Annual LifeSci Partners Corporate Access Event (Jan 5-7), Dermatology Summit (Jan 7), H.C. Wainwright BIOCONNECT (Jan 10-13), and Biotech Showcase 2022 (Jan 10-12, Jan 17-19). Jennifer Good, CEO, will join a panel discussing therapeutic development for itch at the Dermatology Summit. Trevi develops Haduvio™, an investigational therapy for serious conditions like chronic pruritus and chronic cough, with ongoing clinical trials for these indications.

Trevi Therapeutics, a clinical-stage biopharmaceutical company, announced that Dr. Bill Forbes will present at the 5th Annual Dermatology Drug Development Summit on November 18, 2021, in Boston, MA. The presentation will focus on Nalbuphine ER, an investigational therapy aimed at treating pruritus associated with prurigo nodularis. Trevi is conducting Phase 2b/3 trials for Haduvio, targeting chronic conditions mediated through opioid receptors. Haduvio has received Fast Track designation from the FDA for its proposed use in reducing pruritus severity.

Trevi Therapeutics, Inc. (TRVI) reported its financial results for Q3 2021, highlighting a net loss of $7.3 million, a slight improvement from $7.4 million in Q3 2020. As of September 30, 2021, the company had cash and equivalents of $29.3 million. The Phase 2b/3 PRISM trial for Haduvio in chronic pruritus is 90% enrolled, with top-line data expected in 1H 2022. Additionally, Trevi raised $14.8 million post-quarter to support ongoing operations. The company emphasizes the large market potential for its investigational therapy targeting severe itch and chronic cough.

Trevi Therapeutics (Nasdaq: TRVI) announced that its senior leadership will participate in a virtual fireside chat and host investor meetings at the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, with a presentation scheduled for 4 p.m. ET. The event will feature Jennifer Good (President and CEO), Lisa Delfini (CFO), and Bill Forbes (CDO). Investors can access a live webcast on Trevi's website, and an archived replay will be available for 30 days post-conference. Trevi is focused on developing Haduvio, an investigational therapy for serious neurologically mediated conditions.

Trevi Therapeutics (Nasdaq: TRVI) will host a conference call and live audio webcast on November 10 at 4:30 p.m. ET to discuss its Q3 2021 financial results and provide a corporate update. Trevi focuses on developing Haduvio™ (nalbuphine ER) for serious neurological conditions, conducting Phase 2b/3 trials for chronic pruritus and Phase 2 trials for chronic cough in idiopathic pulmonary fibrosis patients. Haduvio has received Fast Track designation by the FDA for prurigo nodularis, although its safety and efficacy are yet to be evaluated.

Trevi Therapeutics (Nasdaq: TRVI) announced that Dr. Bill Forbes, Chief Development Officer, will present at the 11th World Congress on Itch on October 22-23, 2021. The session will focus on the challenges in itch research and the drug development perspective. Trevi is developing Haduvio (nalbuphine ER) for serious neurologically mediated conditions, including chronic pruritus and chronic cough. Haduvio has received Fast Track designation from the FDA for prurigo nodularis. The company aims to address unmet medical needs in itch management.

Trevi Therapeutics (Nasdaq: TRVI) announced its participation in the Alliance Global Partners' Virtual Biotech & Specialty Pharma Conference on October 13, 2021. The company focuses on the development of Haduvio (nalbuphine ER) to treat serious neurologically mediated conditions. Currently, Trevi is conducting a Phase 2b/3 clinical trial for chronic pruritus related to prurigo nodularis and a Phase 2 trial for chronic cough in idiopathic pulmonary fibrosis patients. The investigational therapy has received Fast Track designation from the FDA for moderate to severe pruritus reduction.

Trevi Therapeutics (TRVI) announced a private placement with a healthcare-focused institutional investor, raising approximately $11.8 million. The agreement involves the sale of 2,373,201 shares of common stock and accompanying warrants, priced at $1.62 per share, as well as pre-funded warrants. The company plans to use the proceeds to advance its investigational therapy, Haduvio™, targeting neurologically mediated conditions such as chronic pruritus and chronic cough. The private placement is expected to close on October 4, 2021.